Document is current
Any future updates will be listed below
-
Authors
Wang, Yazhou
Wang, Xiaomin
Liu, Tingting
Wang, Chao
Meng, Qingshuo
Meng, Fanye
Yu, Jiaojiao
Liu, Jinxin
Fan, Yaya
Gennert, David https://orcid.org/0000-0002-8668-3601
Pun, Frank W. https://orcid.org/0000-0001-8801-6645
Aliper, Alex
Ren, Feng https://orcid.org/0000-0001-9157-9182
Zhang, Man
Cai, Xin https://orcid.org/0009-0008-5044-6568
Ding, Xiao https://orcid.org/0000-0003-3482-1870
Zhavoronkov, Alex https://orcid.org/0000-0001-7067-8966
- License Information
-
More Information
Article History
Received: 9 April 2025
Accepted: 21 October 2025
First Online: 28 November 2025
Competing interests
: Insilico Medicine is a company developing an AI-based end-to-end integrated pipeline for drug discovery and development that is engaged in drug discovery programs for aging, fibrosis, and oncology. Insilico Medicine has filed patent applications, including the compounds described herein [(1) Ding, X. et al. Membrane-associated tyrosine-and threonine-specific cdc2-inhibitory kinase (PKMYT1) inhibitors and uses thereof. WO2023155870, published online 24 Aug 2023; (2) Ding, X. et al. Bifunctional compounds for targeting PKMYT1 and methods of use. WO2025040132, published online 27 Feb, 2025]. Insilico Medicine owns the whole patent rights. All authors are current employees of Insilico Medicine.
